Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Tiazofurin inhibits oral cancer growth in vitro and in vivo via upregulation of miR-204 expression

Xiaoying Tang^1,2, Aimin Zhao^1,2 , Yanhuan Hong^1,2

¹Department of Pediatric Stomatology, The Affiliated Stomatological Hospital of Nanchang University, No. 49 Fuzhou Road; ²The Key Laboratory of Oral Biomedicine, Donghu, Nanchang, Jiangxi 330006, China.

For correspondence:- Aimin Zhao Email: RubinGonzaleszip@yahoo.com Tel:+867916361040

Accepted: 21 June 2020 Published: 31 July 2020

Citation: Tang X, Zhao A, Hong Y. Tiazofurin inhibits oral cancer growth in vitro and in vivo via upregulation of miR-204 expression. Trop J Pharm Res 2020; 19(7):1377-1382 doi: 10.4314/tjpr.v19i7.6

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of tiazofurin on proliferation and growth of oral cancer cells, and the associated mechanism(s) of action.

Methods: The effect of tiazofurin on the cytotoxicity of SCC-VII and SCC-25 oral cancer cells were measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, while cell apoptosis was determined by flow cytometry. Western blotting was used for assaying protein expressions.

Results: Tiazofurin inhibited the viability of the oral cancer cells in a concentration-based manner (p < 0 .05). Tiazofurin treatment at a dose of 2.0 µM reduced the proliferation of SCC-VII and SCC-25 cells to 25 and 22 %, respectively. Apoptosis was significantly increased in SCC-VII and SCC-25 cells by tiazofurin treatment, relative to untreated cells (p < 0 .05). Tiazofurin also increased the activation levels of caspase?3 and caspase-9 and downregulated the expressions of p-Akt and p-mTOR in the two cancer cell lines. Moreover, miR-204 expression was significantly promoted in the tiazofurin-treated cells, when compared to control (p < 0 .05). In SCC-VII cells, treatment with tiazofurin suppressed F-actin expression, relative to control.

Conclusion: These results demonstrate that tiazofurin inhibits the viability and proliferation of SCC-VII and SCC-25 cancer cells via induction of apoptosis and activation of caspase-3/caspase-9. Moreover, tiazofurin targets Akt/mTOR pathway, and upregulats the expressions of F?actin and miR-204 in the oral carcinoma cells. These findings suggest that tiazofurin has a potential for use as an effective treatment for oral cancer.

Keywords: Oral cancer, Tiazofurin, Apoptosis, Caspase, Cytotoxicity